Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335556 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
A Phase 2 study of Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
- 20
- Study locations
NCT00335556 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma that has completed, run by Children's Oncology Group. The registered enrollment target is 291 participants, above the 197-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00335556, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin Hydrochloride
- DRUG Etoposide
- DRUG Irinotecan Hydrochloride
- PROCEDURE Conventional Surgery
Study Locations (20)
California
- Southern California Permanente Medical Group - Downey
- Loma Linda University Medical Center - Loma Linda
- Miller Children's Hospital - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital Central California - Madera
- Children's Hospital and Research Center at Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Childrens Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
- University of California San Francisco Medical Center-Parnassus - San Francisco
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham - Birmingham
- University of South Alabama - Mobile
Arizona
- Phoenix Childrens Hospital - Phoenix
- University of Arizona Health Sciences Center - Tucson
Colorado
- Children's Hospital Colorado - Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335556
The ClinicalTrials.gov registry entry for NCT00335556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (48% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00335556 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00335556 about?
NCT00335556 is a clinical study titled "Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors". This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from divid...
What is the current status of trial NCT00335556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2006-06.
What conditions does trial NCT00335556 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage I Renal Cell Cancer.
What interventions are being tested in trial NCT00335556?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin Hydrochloride (DRUG), Etoposide (DRUG), Irinotecan Hydrochloride (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00335556?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00335556 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.